Search results
Results from the WOW.Com Content Network
The FDA said Zepbound’s approval for moderate to severe obstructive sleep apnea in adults with obesity is based on two placebo-controlled studies of 469 adults without type 2 diabetes.
The weight loss drug Zepbound, generically known as tirzepatide, is also now an approved medication to treat obstructive sleep apnea, per a Food and Drug Administration Dec. 20 press release.
The regulator approved the drug for moderate to severe obstructive sleep apnea in adults with obesity, the company said. The approval opens up a wide market of patients for Lilly at a time when ...
The FDA approval for sleep apnea is based on two company-sponsored trials encompassing about 470 participants, one in which patients were being treated with continuous positive air pressure, or ...
Zepbound, a drug approved by the FDA, has been shown to reduce the severity of obstructive sleep apnea in obese adults, although it is not a cure and requires weight loss to be maintained over time.
The Food and Drug Administration (FDA) approved a weight-loss drug to help sleep apnea, becoming the first drug to treat the disorder affecting millions of Americans. On Friday, the federal agency ...
Zepbound, a popular weight loss drug from Eli Lilly, may help people with sleep apnea. Based on recent findings, Eli Lilly plans to submit the material to the U.S. Food and Drug Administration to ...
Zepbound was approved last year to treat obesity. The drug's maker, Eli Lilly, says it reduces the severity of obstructive sleep apnea by 63%.